The Selectivity Advantage The pivotal 1998 study by Raun and colleagues at Novo Nordisk characterized ipamorelin as "the first selective growth hormone secretagogue." The key finding was that even at doses far exceeding those required for GH release, ipamorelin did not produce meaningful elevations in ACTH, cortisol, prolactin, aldosterone, or thyroid-stimulating hormone
Shaking them is like putting a house of cards in an earthquake
Pre-Sleep Routine What you do in the hours before bed significantly impacts sleep quality
Combined with Ipamorelin, protocols aim to enhance fat-reduction while preserving lean muscle & metabolic health, while chosen when central adiposity is the priority without sacrificing muscle mass
The Endocrine Society has not published specific guidelines on peptide-fragment overdose management, though their 2019 growth hormone therapy guidelines provide the closest clinical framework for assessing GH-axis perturbation in overdose contexts [11]